Double-blind, randomized, placebo-controlled single-center study. Nebulized platelet lysate compared to placebo control of saline administered via handheld nebulizer 1x daily for eight weeks to determine effect on lung function in patients with post-COVID-19 Acute Respiratory Disease Syndrome (ARDS).
Platelet lysate will be created from your own blood.
Enrolled participants will have in-person follow-up visits at the clinical site at 1-month, 2-months, 3-months and 6-months from the start of the study.
Only enrolling patients local to the Denver, CO area or surrounding 50 miles.
Criteria:At least 4-weeks post ventilator or oxygen dependent ARDS treated for at least 48 hours in the ICU
Patient is stable enough to have been discharged home
Male or female ages 18-85
Two weeks to 1-year post hospital discharge
Ongoing activity intolerance due to dyspnea related to ARDS
ARDS caused by COVID-19 confirmed through an RNA anti-body test
(other criteria apply)